Home › Funds › Sicart Associates LLC › CGON
Sicart Associates LLC position in CGON
CG ONCOLOGY INC · Health Care
Sicart Associates LLC reported holding 25,000 shares of CGON (CG ONCOLOGY INC) in its Q3 2026 13F filing — a position valued at US$1.5M, representing 0.36% of its reported portfolio and ranking #42 among its reported holdings. Sicart Associates LLC has disclosed CGON holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Sicart Associates LLC's CGON position evolved
Sicart Associates LLC first disclosed a stake in CGON in Q1 2024 at 25,000 shares (US$1.1M). The position peaked in Q2 2026 at 25,000 shares, worth US$1.8M. Across 11 filings, Sicart Associates LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 25,000 shares valued at US$1.5M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 25.00K | $1.10M | New |
| Q2 2024 | 25.00K | $789.25K | Hold |
| Q3 2024 | 25.00K | $943.25K | Hold |
| Q4 2024 | 25.00K | $717.00K | Hold |
| Q1 2025 | 25.00K | $612.25K | Hold |
| Q2 2025 | 25.00K | $650.00K | Hold |
| Q3 2025 | 25.00K | $1.01M | Hold |
| Q4 2025 | 25.00K | $1.04M | Hold |
| Q1 2026 | 25.00K | $1.69M | Hold |
| Q2 2026 | 25.00K | $1.78M | Hold |
| Q3 2026 | 25.00K | $1.50M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGON and 13F data
CGON (CG ONCOLOGY INC) is a Health Care company. 51 other funds we track also report a position in CGON — the largest reported positions include RTW INVESTMENTS, LP (US$605.0M), Decheng Capital LLC (US$452.7M), TCG Crossover Management, LLC (US$260.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGON
- RTW INVESTMENTS, LP 8.51M sh · $604.96M · Q2 2026
- Decheng Capital LLC 6.37M sh · $452.71M · Q2 2026
- TCG Crossover Management, LLC 3.67M sh · $260.77M · Q2 2026
- Foresite Capital Management VI LLC 2.37M sh · $168.36M · Q2 2026
- Seven Fleet Capital Management LP 1.89M sh · $134.02M · Q2 2026
- DV Trading LLC 1.44M sh · $102.27M · Q2 2026
- Avidity Partners Management LP 1.40M sh · $99.40M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.13M sh · $80.39M · Q2 2026
- Foresite Capital Management V, LLC 1.08M sh · $76.67M · Q2 2026
- Logos Global Management LP 1.00M sh · $71.05M · Q2 2026
- ORBIMED ADVISORS LLC 972.80K sh · $69.12M · Q2 2026
- Jefferies Financial Group Inc. 835.34K sh · $59.22M · Q3 2026
More on Sicart Associates LLC
FAQ
How long has Sicart Associates LLC held CGON?
Sicart Associates LLC has disclosed CGON holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is Sicart Associates LLC's current position in CGON?
As of Q3 2026, Sicart Associates LLC holds 25.00K shares of CGON (CG ONCOLOGY INC), valued at $1.50M, representing 0.36% of its reported portfolio and ranking #42.
Has Sicart Associates LLC been buying or selling CGON?
In the latest 13F filing (Q3 2026), Sicart Associates LLC held unchanged its position in CGON. The position peaked in Q2 2026 at 25.00K shares.
Which other funds hold CGON?
Other major institutional holders of CGON include RTW INVESTMENTS, LP, Decheng Capital LLC, TCG Crossover Management, LLC, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.